Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06073821 · ClinicalTrials.gov registry record · Phase 3
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
A Phase 3 study of CLL, sponsored by BeOne Medicines.
- Active
- Registry status
- Phase 3
- Development phase
- 652
- Enrollment target
- 20
- Study locations
NCT06073821 is a Phase 3 study of CLL that is active but no longer recruiting, run by BeOne Medicines. The registered enrollment target is 652 participants, above the 145-participant average among 8 other CLL trials with a reported enrollment target (350% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT06073821, a Phase 3 study of CLL, is active but no longer recruiting, sponsored by BeOne Medicines.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 652 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL)
Conditions Studied
Interventions
- DRUG Zanubrutinib
- DRUG Obinutuzumab
- DRUG Venetoclax
- DRUG Sonrotoclax
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- University of California San Diego (Ucsd) Moores Cancer Center - La Jolla
- Valkyrie Clinical Trials - Los Angeles
- UCLA Department of Medicine Hematologyoncology - Los Angeles
- Chao Family Comprehensive Cancer Center - Orange
- Stanford Medicine - Palo Alto
Florida
- Mount Sinai Comprehensive Cancer Center - Miami Beach
- Moffitt Cancer Center - Tampa
Illinois
- Northwestern University - Chicago
- Illinois Cancercare, Pc - Peoria
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
- Mission Cancer and Blood - Waukee
Alaska
- Alaska Oncology and Hematology, Llc - Anchorage
Colorado
- University of Colorado Cancer Center - Aurora
District of Columbia
- Medstar Georgetown University Hospital - Washington D.C.
Georgia
- Southeastern Regional Medical Center - Newnan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 652 participants |
| Start Date | 2023-11-11 |
| Est. Completion | 2032-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06073821
The ClinicalTrials.gov registry entry for NCT06073821 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 652 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 145-participant average among 8 other CLL trials with a reported enrollment target (350% higher). The listed sponsor is BeOne Medicines, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with CLL appearing as the primary indexed condition, and to 4 interventions - of which Zanubrutinib is the first listed.
NCT06073821 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT06073821 about?
NCT06073821 is a clinical study titled "Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)". The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL)
What is the current status of trial NCT06073821?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 652 participants. The study started on 2023-11-11. Estimated completion is 2032-12.
What conditions does trial NCT06073821 study?
This clinical trial studies the following conditions: CLL.
What interventions are being tested in trial NCT06073821?
The interventions under investigation include: Zanubrutinib (DRUG), Obinutuzumab (DRUG), Venetoclax (DRUG), Sonrotoclax (DRUG).
Who is sponsoring clinical trial NCT06073821?
This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06073821 being conducted?
This trial has 20 study locations across Alaska, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CLL
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
RECRUITING · Phase 3
-
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
RECRUITING · Phase 3
-
Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
RECRUITING · Phase 2
-
Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
ACTIVE NOT RECRUITING · Phase 1
-
Allogeneic Transplantation From Related Haploidentical Donors
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.